Source comparison
CJC-1295 No DAC & Ipamorelin vs MK-677: Research Application Comparison
Administration Subcutaneous injection, 3–5x weekly Oral, once daily MK-677 offers convenience; CJC/Ipa requires injection competence but fewer weekly doses GH Release Pattern Pulsatile, 2–3 hour peaks mimicking natural rhythms Sustained 24-hour elevation Pulsa
This comparison does not assign a generated winner or score.
- Administration
- Subcutaneous injection, 3–5x weekly
- Oral, once daily
- MK-677 offers convenience; CJC/Ipa requires injection competence but fewer weekly doses
- GH Release Pattern
- Pulsatile, 2–3 hour peaks mimicking natural rhythms
- Sustained 24-hour elevation
- Pulsatile preserves receptor sensitivity; sustained may cause desensitization after 6+ months
- Half-Life
- CJC: 6–8 days, Ipamorelin: 2 hours
- 24 hours
- CJC/Ipa allows flexible dosing windows; MK-677 requires daily consistency
- IGF-1 Elevation
- 30–60% increase, peaks 8–16 hours post-dose
- 40–90% sustained increase
- MK-677 produces higher total IGF-1 exposure; CJC/Ipa better mimics physiological variation
- Appetite Effect
- Minimal to none
- Marked increase in 60–80% of subjects
- Critical differentiator for body composition studies. MK-677 complicates deficit maintenance
- Insulin Sensitivity
- Preserved or slightly improved
- Reduced 10–15% (fasting glucose +5–10 mg/dL)
- CJC/Ipa safer for metabolic research; MK-677 requires glucose monitoring
- Cost per Month
- $80–$150 for research-grade peptides
- $40–$80 for pharmaceutical-grade powder
- MK-677 more economical but side effect management adds hidden costs
- Ideal Research Application
- Tissue repair, anti-aging protocols prioritizing physiological patterns
- Elderly sarcopenia, cachexia models requiring sustained anabolism
- CJC/Ipa for optimization studies; MK-677 for wasting syndrome models